Intersect ENT

Intersect ENT (Nasdaq:XENT) is dedicated to improving the quality of life for patients with ear, nose and throat conditions. The company markets the first and only drug-releasing sinus implants, PROPEL and PROPEL mini, which are clinically proven to improve surgical outcomes for patients with chronic sinusitis. The products release an advanced steroid with anti-inflammatory properties directly into the sinus lining, then dissolve, maintaining the open passages created in ethmoid sinus surgery. In addition, Intersect ENT is pursuing clinical trials designed to support expanded indications and to assess two new investigational drug-eluting implants to provide ENT physicians with additional options to treat patients with chronic sinusitis less invasively and more cost effectively. Chronic sinusitis is an inflammatory condition leading to debilitating symptoms and chronic infections, and is one of the most costly conditions to U.S. employers.
Type
Public
HQ
Menlo Park, US
Employees
275 (est)+4%
Intersect ENT has headquartered in Menlo Park, US

Key People at Intersect ENT

Lisa Earnhardt

Lisa Earnhardt

President & CEO
Monika De Martini

Monika De Martini

CFO
Amy Couel wolbeck

Amy Couel wolbeck

Vice President, Regulatory Affairs and Quality
Robrt Binney

Robrt Binney

Vice President of Sales
Susan P Stimson

Susan P Stimson

Vice President of Marketing
Rich Kaufman

Rich Kaufman

Senior Vice President and Chief Operating Officer

Intersect ENT Locations

Menlo Park, US

Intersect ENT Metrics

Intersect ENT Summary

Market capitalization

$264 M

Closing share price

$9.45
Intersect ENT's latest market capitalization is $264 M.

Intersect ENT Market Value History

Intersect ENT Online Presence

Intersect ENT Company Life

You may also be interested in